Serial Number
98405995
Owner
Earli Inc.Attorney
Ted D. KarrFirst Use Date
Sep 25, 2025
Filing Date
Feb 14, 2024
TURN CANCER AGAINST ITSELF Trademark
Serial Number: 98405995 • Registration: 8264526
Trademark Classes
Owner Contact Info
Legal Representation
Correspondence Address
Ted D. Karr Berkeley Law & Technology Group LLP
7710 Rialto Blvd, Suite 100
Austin, TX 78735
United States
Trademark Details
Filing Date
February 14, 2024
Registration Date
May 19, 2026
First Use Anywhere
September 25, 2025
First Use in Commerce
September 25, 2025
Published for Opposition
October 22, 2024
Goods & Services
Products for the prevention of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the detection of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the localization of cancer in humans, namely, pharmaceutical products to express a synthetic biomarker for localization of cancer; Products for the therapy of cancer in humans, namely, pharmaceutical products to express a treatment agent for treating cancer; Products for the prevention of cancer in animals, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the detection of cancer in animals, namely, pharmaceutical products to express a synthetic biomarker for detecting cancer; Products for the therapy of cancer in animals, namely, pharmaceutical products to express a treatment agent for treating cancer
Medical services for the prevention of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for detecting cancer; Medical services for the detection of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for detection of cancer; Medical services for the localization of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for the localization of cancer; Medical services for the therapy of cancer in humans, namely, medical assay processing provided by medical laboratories and medical analysis services for treating cancer; Medical services for the prevention of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for detecting cancer; Medical services for the detection of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for detection of cancer; Medical services for the therapy of cancer in animals, namely, medical assay processing provided by medical laboratories and medical analysis services for the treatment of cancer